Controversial Duchenne MD player Solid Bio takes another hit, laying off staffers in a bid to weather FDA hold
With their gene therapy program for Duchenne muscular dystrophy frozen in regulatory limbo with no evident sign of a near-term thaw, Solid Biosciences $SLDB is axing staff, bidding top execs goodbye and circling the wagons in a bid to survive the storm.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
